George Frangeskides, Exec-Chair at Alba Mineral Resources, discusses grades at the Clogau Gold Mine. Watch the full video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPhysiomics Regulatory News (PYC)

Share Price Information for Physiomics (PYC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1.30
Bid: 1.20
Ask: 1.40
Change: 0.00 (0.00%)
Spread: 0.20 (16.667%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 1.30
PYC Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Contract award

23 Dec 2019 07:00

RNS Number : 7178X
Physiomics PLC
23 December 2019
 

23 December 2019

Physiomics plc

("Physiomics") or (the "Company")

 

 

Contract award

 

Physiomics signs further project agreement with CellCentric

 

Physiomics plc (AIM: PYC), the oncology consultancy using mathematical models to support the development of cancer treatment regimens for the biopharma industry, is delighted to announce that it has been awarded a further contract by existing UK based biotech client, CellCentric. The value of the contract is not disclosed but is expected to complete in the first half of 2020.

 

The project will involve pharmacokinetic and pharmacodynamic modelling and build on the work completed over the course of 2019 in support of the clinical development of CellCentric's lead asset CCS1477. This is a first in class small molecule inhibitor of p300/CBP, currently in Phase 1/2 trials for the treatment of late stage, drug-resistant prostate cancer as well as haematological malignancies.

 

A summary of some of the work that the Company has previously completed with CellCentric is available as a case study on the Physiomics website and can be accessed using the following hyperlink: https://www.physiomics.co.uk/wp-content/uploads/2019/03/CC-case-study.pdf.

 

Dr Jim Millen, CEO said:

"We are looking forward to continuing to work with CellCentric, one of the UK's most exciting young biotech companies."

 

Enquiries:

 

Physiomics plc

Dr Jim Millen, CEO

+44 (0)1865 784 980

 

Strand Hanson Ltd (NOMAD)

Richard Tulloch & James Dance

+44 (0) 20 7409 3494

 

Hybridan LLP (Broker)

Claire Louise Noyce

+44 (0) 20 3764 2341

 

 

Notes to Editor

 

About Physiomics

 

Physiomics® is an oncology consultancy which uses mathematical PKPD models as well as its proprietary Virtual Tumour™ technology to predict the effects of cancer drugs and treatments and improve the success rate of drug discovery and development projects. The predictive capability of Virtual Tumour has been confirmed by 55 projects, involving over 25 targets and 60 drugs, and has worked with clients such as Merck KGaA, Merck & Co, Bayer and Lilly.

 

Based in Oxford UK, the Company works with clients worldwide to support their pre-clinical and clinical oncology development programs. Its team of scientists and computer modelling experts provide bespoke solutions encompassing data, analytics and insight.

 

Physiomics senior management has academic and commercial expertise, including over 90 years collectively of working in oncology and/or computational biology and over 100 publications in peer reviewed journals.

 

For more information please visit:

www.physiomics-plc.com

www.twitter.com/Physiomics

www.linkedin.com/company/physiomics-plc/

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
NRAPGGCUPUPBGQU
Date   Source Headline
21st Mar 20247:00 amRNSIMC Presentation on Company Website
18th Mar 20247:00 amRNSContract Award
7th Mar 20247:00 amRNSInterim Results
1st Mar 20243:00 pmRNSNotice of Results and Investor Presentation
19th Feb 20247:00 amRNSContract Award
6th Feb 20247:00 amRNSOptions Award
5th Feb 20247:00 amRNSContract Award
2nd Feb 20247:00 amRNSIMC Presentation on Company Website
23rd Jan 20247:00 amRNSIMC Presentation on Board Changes
22nd Jan 20247:00 amRNSBoard Changes
21st Nov 20233:30 pmRNSResult of AGM
10th Nov 20233:14 pmRNSBusiness Update Presentation
10th Nov 20237:00 amRNSInnovate UK grant award
18th Oct 20237:00 amRNSNotice of AGM
4th Oct 20237:00 amRNSChange of Registered Office
3rd Oct 20237:00 amRNSSenior Management Announcement
28th Sep 20237:00 amRNSAnnual Financial Report
4th Sep 20237:00 amRNSSenior Management Update
31st Aug 20231:00 pmRNSContract Award
31st Aug 20237:00 amRNSContract Award
8th Aug 20237:45 amRNSContract Award
4th Aug 20237:00 amRNSContract Award
25th Jul 20237:00 amRNSDirector Dealing
18th Jul 20237:00 amRNSDirector Dealing
29th Jun 20237:00 amRNSCompletion of Placing, Subscription & Retail Offer
27th Jun 20237:01 amRNSWRAP Retail Offer for up to £150,000
27th Jun 20237:00 amRNSCompletion of Equity Fundraise
31st May 20237:00 amRNSCollaboration with The University of Sheffield
23rd May 20237:00 amRNSTrading Update
9th May 20237:00 amRNSPublication of article in Frontiers in Oncology
26th Apr 20237:00 amRNSCollaborative Services Agreement
14th Apr 20237:00 amRNSPhysiomics to present at AACR Annual Meeting
4th Apr 20237:00 amRNSTrading and Company Update
28th Mar 20237:00 amRNSAnnouncement of Collaboration
10th Mar 20237:00 amRNSContract announcement
7th Mar 20237:00 amRNSInterim Results
13th Jan 20237:00 amRNSChange in role of board Director
11th Jan 20237:00 amRNSContract announcement
9th Jan 20237:00 amRNSCompletion of PARTNER study
22nd Nov 20224:00 pmRNSResult of AGM
10th Nov 20228:50 amRNSContract award
9th Nov 20227:00 amRNSPYC to present and exhibit at SITC Annual Meeting
27th Oct 20227:00 amRNSAnnual Report and AGM Notice
14th Oct 20227:00 amRNSConference Attendance
12th Oct 20227:00 amRNSContract Award
4th Oct 20227:00 amRNSContract Award
29th Sep 20227:00 amRNSInterim Results
9th Sep 20227:00 amRNSNotice of Results
1st Sep 20227:00 amRNSAppointment of Independent Non-Executive Director
7th Jul 20227:00 amRNSTrading update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.